349 related articles for article (PubMed ID: 34299097)
1. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.
Soliman AM; Das S; Teoh SL
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299097
[TBL] [Abstract][Full Text] [Related]
2. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.
Soliman AM; Lin TS; Mahakkanukrauh P; Das S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066062
[TBL] [Abstract][Full Text] [Related]
3. Established and Novel Prognostic Biomarkers in Multiple Myeloma.
Bustoros M; Mouhieddine TH; Detappe A; Ghobrial IM
Am Soc Clin Oncol Educ Book; 2017; 37():548-560. PubMed ID: 28561668
[TBL] [Abstract][Full Text] [Related]
4. Emerging biomarkers in Multiple Myeloma: A review.
Gupta N; Sharma A; Sharma A
Clin Chim Acta; 2020 Apr; 503():45-53. PubMed ID: 31901479
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
Bolli N; Biancon G; Moarii M; Gimondi S; Li Y; de Philippis C; Maura F; Sathiaseelan V; Tai YT; Mudie L; O'Meara S; Raine K; Teague JW; Butler AP; Carniti C; Gerstung M; Bagratuni T; Kastritis E; Dimopoulos M; Corradini P; Anderson KC; Moreau P; Minvielle S; Campbell PJ; Papaemmanuil E; Avet-Loiseau H; Munshi NC
Leukemia; 2018 Dec; 32(12):2604-2616. PubMed ID: 29789651
[TBL] [Abstract][Full Text] [Related]
6. Toward personalized treatment in multiple myeloma based on molecular characteristics.
Pawlyn C; Davies FE
Blood; 2019 Feb; 133(7):660-675. PubMed ID: 30587529
[TBL] [Abstract][Full Text] [Related]
7. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.
Agnelli L; Tassone P; Neri A
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S55-68. PubMed ID: 23614397
[TBL] [Abstract][Full Text] [Related]
9. The role of circulating miRNAs in multiple myeloma.
Zhang J; Xiao X; Liu J
Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
[TBL] [Abstract][Full Text] [Related]
10. Utilizing next-generation sequencing in the management of multiple myeloma.
Lionetti M; Neri A
Expert Rev Mol Diagn; 2017 Jul; 17(7):653-663. PubMed ID: 28524737
[TBL] [Abstract][Full Text] [Related]
11. Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma.
Buedts L; Smits S; Ameye G; Lehnert S; Ding J; Delforge M; Vermeesch J; Boeckx N; Tousseyn T; Michaux L; Vandenberghe P; Dewaele B
Genes Chromosomes Cancer; 2020 Aug; 59(8):465-471. PubMed ID: 32259320
[TBL] [Abstract][Full Text] [Related]
12. Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
[TBL] [Abstract][Full Text] [Related]
13. Tracking myeloma tumor DNA in peripheral blood.
Waldschmidt JM; Vijaykumar T; Knoechel B; Lohr JG
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101146. PubMed ID: 32139012
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive biomarker developments in multiple myeloma.
Wallington-Beddoe CT; Mynott RL
J Hematol Oncol; 2021 Sep; 14(1):151. PubMed ID: 34556161
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease analysis in myeloma - when, why and where.
Yanamandra U; Kumar SK
Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting MEK in MAPK pathway-activated myeloma.
Heuck CJ; Jethava Y; Khan R; van Rhee F; Zangari M; Chavan S; Robbins K; Miller SE; Matin A; Mohan M; Ali SM; Stephens PJ; Ross JS; Miller VA; Davies F; Barlogie B; Morgan G
Leukemia; 2016 Apr; 30(4):976-80. PubMed ID: 26228812
[No Abstract] [Full Text] [Related]
17. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A; Perumal D; Melnekoff D; Readhead B; Kidd BA; Leshchenko V; Kuo PY; Keats J; DeRome M; Yesil J; Auclair D; Lonial S; Chari A; Cho HJ; Barlogie B; Jagannath S; Dudley JT; Parekh S
Leukemia; 2018 Jan; 32(1):120-130. PubMed ID: 28642592
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
Petrackova A; Minarik J; Sedlarikova L; Libigerova T; Hamplova A; Krhovska P; Balcarkova J; Pika T; Papajik T; Kriegova E
Br J Haematol; 2020 May; 189(4):e122-e125. PubMed ID: 32130732
[No Abstract] [Full Text] [Related]
19. Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.
Yang Q; Li K; Li X; Liu J
Int J Med Sci; 2020; 17(14):2063-2076. PubMed ID: 32922167
[No Abstract] [Full Text] [Related]
20. New tools for diagnosis and monitoring of multiple myeloma.
San-Miguel JF; Paiva B; Gutiérrez NC
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
